Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

While early-stage, the Adagene deal is another example of Sanofi's determination to bolster its R&D pipeline via a string of deals, including a $5.2 billion, strategic-level alliance with UK ...

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Sanofi’s SNY stock has declined 10.2% in the past three months.However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the ...

Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025KT-621 Phase 1b trial in atopic dermatitis ...

The biopharma industry now has the most extensive and varied clinical pipeline to date ... by 208 percentage points (see more details here). Sanofi (NASDAQ:SNY) is a global healthcare company ...

PARIS – L’Oréal has agreed to sell about 29.6 million Sanofi shares to Sanofi for approximately 3 billion euros. The transaction is to be priced at 101.50 euros per share, the French beauty ...